Metabolic syndrome – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Thu, 18 Jun 2026 04:07:44 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Metabolic syndrome – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on the Effects of Roxadustat and Placebo on Cardiovascular Risk Factors and Metabolic Syndrome in Patients https://clinicaltrials.eu/trial/study-on-the-effects-of-roxadustat-and-placebo-on-cardiovascular-risk-factors-and-metabolic-syndrome-in-patients/ Wed, 29 Apr 2026 15:05:45 +0000 https://clinicaltrials.eu/trial/study-on-the-effects-of-roxadustat-and-placebo-on-cardiovascular-risk-factors-and-metabolic-syndrome-in-patients/ This clinical trial is focused on studying the effects of a medication called Evrenzo, which contains the active substance roxadustat. The study is aimed at individuals with risk factors for cardiovascular disease and those with metabolic syndrome. Metabolic syndrome is a group of conditions that occur together, increasing the risk of heart disease, stroke, and type 2 diabetes. The purpose of the study is to explore how roxadustat affects glucose and lipid metabolism, as well as cardiovascular function.

Participants in the study will receive either the active medication, Evrenzo, or a placebo, which looks like the medication but does not contain the active substance. The study will last for a period of eight weeks, during which participants will take the medication orally in the form of film-coated tablets. Throughout the study, various health parameters will be monitored, including cholesterol levels, insulin resistance, glucose tolerance, body composition, blood pressure, and muscle blood flow.

The trial aims to provide insights into how roxadustat can influence factors related to heart health and metabolism. By understanding these effects, researchers hope to contribute to better management of conditions associated with cardiovascular disease and metabolic syndrome. The study is expected to conclude by the end of 2025.

]]>